Granted Patent B2

US 10,737,082 · App. 15/744,385 · Granted Aug 11, 2020

Abstract

Claims (17)

1. A method of delivering one or more agents to one or more lymphatic tissues of a subject, the method comprising:

(a) applying one or more delivery devices having between 2 and 50,000 delivery structures to one or more sites of a skin of a subject having lymphatic vasculature, wherein the one or more delivery devices contacts one or more layers of epidermis with one or more reversible permeability enhancers comprising a chemical, physical or electrical permeability enhancer that induces a-reversible increase in permeability of one or more barrier cells of the epidermis to at least one or more agents;

(b) administering a total liquid dosage in between 2 and 50,000 sub-doses of the one or more agents at a controlled administration flow rate of from about 0.01 μl/hr to about 100 μl/hr per each of the delivery structures at a total combined controlled administration flow rate of about 0.02 μl/hr/cm 2 to about 50,000 μl/hr/cm 2 based on a total surface area of the one or more delivery devices that is in contact with the skin of the subject,

wherein each sub-dose of the one or more agents is independently administered, in an administering step, to a plurality of independent depths ranging from about 1 m to about 500 pm beyond a most superficial surface layer of the epidermis of the subject, but still within the epidermis of the subject exhibiting a Gaussian distribution of delivery depths within the epidermis prior to any subsequent diffusion or movement of the one or more agents within the epidermis; and wherein following the administering step, the one or more agents moves or diffuses deeper through the epidermis through a basal layer of the epidermis and into at least a portion of underlying viable dermis to achieve an uptake of a portion of the one or more agents by one or more susceptible lymphatic capillary plexus,

wherein the administration to the epidermis achieves a greater uptake of the one or more agents to the lymphatic vasculature compared to intravenous, intradermal, or subcutaneous delivery of the one or more agents; and

wherein following administration, the permeability of the one or more barrier cells returns to a state prior to contact of the epidermis with the one or more permeability enhancers.

2. The method according to claim 1 , wherein the plurality of independent depths within a viable epidermis layer is from about 1 μm to about 250 μm beyond a deepest non-viable epidermal layer but still within the viable epidermis layer.

3. The method according to claim 1 , wherein the delivery device comprises an array comprising between 2 and 50,000 of the delivery structures in fluid communication with the one or more agents in a liquid carrier vehicle,

wherein the delivery device comprises a means for controlling the administration flow rate including at least one component selected from a group consisting of: a pump, a syringe, a pen, an elastomer membrane or any combination thereof:

wherein the delivery structures comprise a means for penetrating at least a most superficial layer of the epidermis; and

wherein the one or more agents in a liquid carrier vehicle is delivered by the delivery structures to the plurality of independent depths within a viable epidermis layer of a the subject, thereby administering the between 2 and 50,000 sub-doses of the one or more agents.

4. The method according to claim 3 , wherein the delivery structures comprise needles.

5. The method according to claim 1 , wherein the one or more agents is delivered to a tissue volume of the epidermis encompassing the one or more agents prior to any subsequent diffusion or movement of the one or more agents within the epidermis of about 0.7 mm 3 to about 2,500 mm 3 .

6. The method according to claim 1 , wherein the one or more permeability enhancers is one or more chemical, physical, or electrical permeability enhancers.

7. The method according to claim 1 , wherein administration of one or more agents achieves a dermal interstitial fluid pressure in an underlying dermis layer beneath a site of administration of about 1 mmHg to about 15 mmHg.

8. The method according to claim 1 , wherein a relative concentration of one or more agents within the one or more lymphatic tissues is about 1.25 fold to about 50 fold more than intravenous, intradermal, or subcutaneous delivery of the one or more agents.

9. The method according to claim 1 , wherein a ratio of an initial dose of one or more agents localized per gram of lymph node tissue to a whole blood tissue is from about 5:1 to about 15:1 after about 36 hours.

Assignments (8)